JP2020513032A5 - - Google Patents

Download PDF

Info

Publication number
JP2020513032A5
JP2020513032A5 JP2020502532A JP2020502532A JP2020513032A5 JP 2020513032 A5 JP2020513032 A5 JP 2020513032A5 JP 2020502532 A JP2020502532 A JP 2020502532A JP 2020502532 A JP2020502532 A JP 2020502532A JP 2020513032 A5 JP2020513032 A5 JP 2020513032A5
Authority
JP
Japan
Prior art keywords
subject
composition
sequestering
metabolite
behavioral symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020502532A
Other languages
English (en)
Japanese (ja)
Other versions
JP6978122B2 (ja
JP2020513032A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/025607 external-priority patent/WO2018183986A1/en
Publication of JP2020513032A publication Critical patent/JP2020513032A/ja
Publication of JP2020513032A5 publication Critical patent/JP2020513032A5/ja
Application granted granted Critical
Publication of JP6978122B2 publication Critical patent/JP6978122B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020502532A 2017-03-31 2018-03-31 自閉症および関連障害の治療および予防のための腸管選択的隔離剤 Expired - Fee Related JP6978122B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762480039P 2017-03-31 2017-03-31
US62/480,039 2017-03-31
PCT/US2018/025607 WO2018183986A1 (en) 2017-03-31 2018-03-31 Gut-selective sequestering agents for the treatment and prevention of autism and related disorders

Publications (3)

Publication Number Publication Date
JP2020513032A JP2020513032A (ja) 2020-04-30
JP2020513032A5 true JP2020513032A5 (enExample) 2021-04-15
JP6978122B2 JP6978122B2 (ja) 2021-12-08

Family

ID=63677186

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020502532A Expired - Fee Related JP6978122B2 (ja) 2017-03-31 2018-03-31 自閉症および関連障害の治療および予防のための腸管選択的隔離剤

Country Status (9)

Country Link
US (4) US10617718B2 (enExample)
EP (1) EP3600349A4 (enExample)
JP (1) JP6978122B2 (enExample)
KR (1) KR102328323B1 (enExample)
CN (2) CN110944650B (enExample)
AU (3) AU2018243836B9 (enExample)
BR (1) BR112019020289A2 (enExample)
CA (2) CA3191747A1 (enExample)
WO (1) WO2018183986A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102328323B1 (ko) 2017-03-31 2021-11-19 엑시얼 테라퓨틱스, 인크. 자폐증 및 관련 장애의 치료 및 예방을 위한 장-선택적 봉쇄제
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
WO2021011481A1 (en) * 2019-07-12 2021-01-21 The General Hospital Corporation Anti-inflammatory factors
JP7607659B2 (ja) * 2019-12-19 2024-12-27 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド トマトの搾りかすを用いたイヌの上昇した4-エチルフェニル硫酸と関連付けられた状態の治療およびリスクを低減する組成物および方法ならびにそのような状態のリスクにあるイヌを特定する方法
US20240197795A1 (en) * 2020-07-27 2024-06-20 Boadie DUNLOP Assessment and treatment of depression, anxiety, or related disorders
CN113440522B (zh) * 2021-07-29 2022-12-13 中山大学附属第七医院(深圳) 一种吲哚丙酸在制备用于治疗自闭症药物中的应用
CN115825314A (zh) * 2021-09-17 2023-03-21 中国科学院深圳先进技术研究院 一种阿尔兹海默症生物标志物s-甲基-5′-硫代腺苷及其应用
WO2023154966A1 (en) * 2022-02-14 2023-08-17 Axial Therapeutics, Inc. Compositions and methods for sequestering metabolites in the gastrointestinal tract
WO2023154547A1 (en) 2022-02-14 2023-08-17 Axial Therapeutics, Inc. Colon targeted drug delivery
CN116990395A (zh) * 2022-04-26 2023-11-03 中国科学院深圳先进技术研究院 一种基于粪便的阿尔兹海默症生物标志物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761284A (en) * 1977-12-27 1988-08-02 Kureha Kagaku Kogy Kabushiki Kaisha Antidote including activated carbon particles
JPS5673542A (en) * 1979-11-22 1981-06-18 Kureha Chem Ind Co Ltd Adsorbent
GB9611437D0 (en) 1995-08-03 1996-08-07 Secr Defence Biomaterial
US7651974B2 (en) 2002-11-01 2010-01-26 Kureha Chemical Industry Co., Ltd. Adsorbent for oral administration
JP2008523100A (ja) * 2004-12-13 2008-07-03 アリーナ ファーマシューティカルズ, インコーポレイテッド 5ht2c受容体に関連した疾患の治療に有用な5ht2c受容体のモジュレータとしてのn−ビアリール及びn−アリールヘテロアリール2−置換ピペラジン誘導体
WO2010102218A1 (en) * 2009-03-05 2010-09-10 Mithridion, Inc. Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
KR101593287B1 (ko) * 2011-03-04 2016-02-11 가부시끼가이샤 구레하 정제형의 경구 투여용 조성물 및 그의 제조 방법
US20140213534A1 (en) * 2011-05-23 2014-07-31 Thomas Jefferson University Intestinal hyperpermeability and prevention of systemic disease
GB201204696D0 (en) * 2012-03-16 2012-05-02 Ucl Business Plc Therapy
CN114949001A (zh) * 2012-08-29 2022-08-30 加州理工学院 孤独症谱系障碍的诊断和治疗
TWI520751B (zh) 2013-02-22 2016-02-11 吳羽股份有限公司 經口投予用吸附劑及腎疾病治療劑及肝疾病治療劑
MX2016000293A (es) 2013-07-09 2016-06-21 Stemina Biomarker Discovery Inc Biomarcadores del trastrono del espectro autista.
KR20160034352A (ko) * 2013-07-23 2016-03-29 유로-셀티큐 에스.에이. 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
US9763903B2 (en) * 2013-10-22 2017-09-19 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US20150111878A1 (en) * 2013-10-22 2015-04-23 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
WO2015150590A1 (en) * 2014-04-04 2015-10-08 Biotechnobel Sa Composition for prevention and/or treatment of chronic inflammation and concomitant biofilms in the gastrointestinal tract
KR102328323B1 (ko) 2017-03-31 2021-11-19 엑시얼 테라퓨틱스, 인크. 자폐증 및 관련 장애의 치료 및 예방을 위한 장-선택적 봉쇄제

Similar Documents

Publication Publication Date Title
JP2018513107A5 (enExample)
JP2021525729A5 (enExample)
JP2014506321A5 (enExample)
JP2016534153A5 (enExample)
CN109310769A (zh) 用rxr激动剂与甲状腺激素的组合的自身免疫疾病的治疗
JP2020531543A (ja) アマンタジン組成物、その調製、および使用方法
WO2015144059A1 (zh) 具有镇咳活性的细辛总多糖提取物及其提取方法和应用
JP2018529747A5 (enExample)
JP2019503335A (ja) ジメチルアミノミケリオリドの使用
Mollica et al. Obstructive sleep apnea and cardiovascular risks in the elderly population
JP4180258B2 (ja) IgE抗体抑制剤および食品
IL309959A (en) Rapid relief of motor fluctuations in parkinson’s disease
CN102641350B (zh) 温肺平喘颗粒及其制备工艺
CN105078899B (zh) 一种恩诺沙星复层高分子矫味骨架微粒及其制备方法
JP2020509036A5 (enExample)
CN102845365A (zh) 维医动物模型的造模方法、模型、反证和综合评价方法
Lemko et al. The usage of haloaerosoltherapy in the rehabilitational treatment of children with reccurent bronchitis
CN105456201B (zh) 氨溴索沙丁胺醇微丸的制备方法
RU2278670C2 (ru) Способ лечения бронхиальной астмы у детей в период ремиссии
JP2021525796A (ja) 神経疾患の阻害
RU2347576C1 (ru) Средство для коррекции гиперреактивности дыхательных путей у детей
CN105343040B (zh) 氨溴索沙丁胺醇散剂的制备方法
CN105326796B (zh) 氨溴索沙丁胺醇散剂
CN110152003B (zh) 一种用于治疗copd的复方药物及其制备方法
CN105326804B (zh) 氨溴索沙丁胺醇滴丸